MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
51.65
+2.28
+4.62%
After Hours: 51.65 0 0.00% 17:12 02/06 EST
OPEN
50.01
PREV CLOSE
49.37
HIGH
51.99
LOW
50.01
VOLUME
893.96K
TURNOVER
--
52 WEEK HIGH
57.65
52 WEEK LOW
29.16
MARKET CAP
2.96B
P/E (TTM)
-151.5552
1D
5D
1M
3M
1Y
5Y
1D
Biogen projects 2026 revenue drop despite Q4 beat
Seeking Alpha · 21h ago
Weekly Report: what happened at SUPN last week (0126-0130)?
Weekly Report · 5d ago
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Seeking Alpha · 5d ago
Supernus Revises Merger Milestone Payment Obligations Agreement
TipRanks · 01/28 22:49
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
TipRanks · 01/28 12:39
Weekly Report: what happened at SUPN last week (0119-0123)?
Weekly Report · 01/26 09:43
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
Barchart · 01/26 03:20
Bank of America Securities Remains a Buy on Supernus Pharmaceuticals (SUPN)
TipRanks · 01/20 11:47
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.